EVGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

275.00K

-82.93%

-0.260

-533.33%

3.00M

+22.75%

-0.320

-15.79%

500.00K

-43.44%

-0.460

-8%

Estimates Revision

The market is revising No Change the revenue expectations for Evogene Ltd. (EVGN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -13.95%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-13.95%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Evogene Ltd (EVGN.O) is -0.97, compared to its 5-year average forward P/E of -2.00. For a more detailed relative valuation and DCF analysis to assess Evogene Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.00

Current PE

-0.97

Overvalued PE

-0.00

Undervalued PE

-3.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.59

Current EV/EBITDA

-1.57

Overvalued EV/EBITDA

0.21

Undervalued EV/EBITDA

-1.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

41.15

Current PS

3.53

Overvalued PS

133.46

Undervalued PS

-51.16

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

EVGN News & Events

Events Timeline

No data

News

7.5

01-07Newsfilter

Evogene Partners with Unravel to Develop Myelin Repair Therapies

2.0

2025-12-30PRnewswire

Evogene Appoints Dr. Olga Nissan as VP of Business Development

5.0

2025-12-30Newsfilter

Evogene Appoints Dr. Olga Nissan as VP of Business Development to Enhance AI-Driven Drug Discovery

People Also Watch

Frequently Asked Questions

What is Evogene Ltd (EVGN) stock price today?

The current price of EVGN is 1.11 USD — it has increased 0.45 % in the last trading day.

What is Evogene Ltd (EVGN)'s business?

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

What is the price predicton of EVGN Stock?

Wall Street analysts forecast EVGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVGN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Evogene Ltd (EVGN)'s revenue for the last quarter?

Evogene Ltd revenue for the last quarter amounts to 312.00K USD, decreased -82.07 % YoY.

What is Evogene Ltd (EVGN)'s earnings per share (EPS) for the last quarter?

Evogene Ltd. EPS for the last quarter amounts to 0.44 USD, decreased -133.59 % YoY.

What changes have occurred in the market's expectations for Evogene Ltd (EVGN)'s fundamentals?

How many employees does Evogene Ltd (EVGN). have?

Evogene Ltd (EVGN) has 117 emplpoyees as of January 10 2026.

What is Evogene Ltd (EVGN) market cap?

Today EVGN has the market capitalization of 9.68M USD.